Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Doki, Yuichiro; A. Ajani, Jaffer; Kato, Ken; Xu, Jianming; Wyrwicz, Lucjan; Motoyama, Satoru; Ogata, Takashi; Kawakami, Hisato; Hsu, Chih-Hung; Adenis, Antoine; El Hajbi, Farid; Di Bartolomeo, Maria; I. Braghiroli, Maria; Holtved, Eva; A. Ostoich, Sandra; R. Kim, Hye; Ueno, Masaki; Mansoor, Wasat; Yang, Wen-Chi; Liu, Tianshu; Bridgewater, John; Makino, Tomoki; Xynos, Ioannis; Liu, Xuan; Lei, Ming; Kondo, Kaoru; Patel, Apurva; Gricar, Joseph; Chau, Ian; Kitagawa, Yuko

doi:10.1056/nejmoa2111380

Public

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Published in New England Journal of Medicine • Feb 2, 2022

Authors:

Yuichiro Doki

Jaffer A. Ajani

Ken Kato

Abstract

BACKGROUND: First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma. METHODS: In this op...

Subject

Nivolumab

Medicine

Ipilimumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!